A detailed history of Commonwealth Equity Services, LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 89,120 shares of ALT stock, worth $691,571. This represents 0.0% of its overall portfolio holdings.

Number of Shares
89,120
Previous 87,110 2.31%
Holding current value
$691,571
Previous $579,000 5.53%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$5.5 - $8.1 $11,055 - $16,281
2,010 Added 2.31%
89,120 $547,000
Q2 2024

Jul 31, 2024

BUY
$5.91 - $10.23 $42,345 - $73,297
7,165 Added 8.96%
87,110 $579,000
Q1 2024

Apr 29, 2024

BUY
$8.22 - $13.81 $157,593 - $264,765
19,172 Added 31.55%
79,945 $814,000
Q4 2023

Feb 06, 2024

BUY
$2.14 - $11.62 $42,292 - $229,646
19,763 Added 48.19%
60,773 $684,000
Q3 2023

Oct 23, 2023

BUY
$2.4 - $3.45 $9,468 - $13,610
3,945 Added 10.64%
41,010 $107,000
Q2 2023

Aug 10, 2023

BUY
$3.45 - $5.97 $23,101 - $39,975
6,696 Added 22.05%
37,065 $131,000
Q1 2023

May 11, 2023

BUY
$4.19 - $16.83 $57,905 - $232,590
13,820 Added 83.51%
30,369 $128,000
Q3 2022

Nov 14, 2022

BUY
$10.67 - $22.41 $176,577 - $370,863
16,549 New
16,549 $211,000
Q4 2021

Jan 31, 2022

SELL
$8.69 - $12.48 $167,325 - $240,302
-19,255 Closed
0 $0
Q3 2021

Oct 29, 2021

SELL
$8.43 - $16.81 $4,063 - $8,102
-482 Reduced 2.44%
19,255 $217,000
Q2 2021

Aug 11, 2021

BUY
$9.85 - $16.46 $76,849 - $128,420
7,802 Added 65.37%
19,737 $194,000
Q1 2021

May 04, 2021

BUY
$12.71 - $24.31 $151,693 - $290,139
11,935 New
11,935 $168,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $380M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.